Previous research has shown SGLT2 inhibitors to have antiproliferative effects against different types of tumors, including pancreatic carcinoma, due to their blockage of glucose reuptake in cells and suppressing glycolysis via the PI3K/AKT/mTOR pathway. The gene discussed is MTOR; the disease is exocrine pancreatic carcinoma.